ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "positron emission tomography (PET)"

  • Abstract Number: 062 • 2020 Pediatric Rheumatology Symposium

    Is Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) a Reliable Tool for Detecting Vascular Activity in Treated Childhood-Onset Takayasu’s Arteritis (C-TA)? A Multicenter Study

    Gleice Russo1, Rosa Pereira 2, Nadia Aikawa 3, Clovis Silva 4, Lucia Campos 5, Ana Paula Sakamoto 6, Alexandre Souza 7 and Maria Teresa Terreri 4, 1Universidade Federal de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 2University of São Paulo, Sao Paulo, Brazil, 3University of Sao Paulo, Sao Paulo, Brazil, 4Sao Paulo, Brazil, 5children's institute, Sao Paulo, Brazil, 6São Paulo, Brazil, 7UNIFESP-EPM, São Paulo, Brazil

    Background/Purpose: The improving therapeutic approach towards childhood-onset Takayasu’s arteritis (c-TA) has decreased the mortality rate over the years and increased concerns on how to improve…
  • Abstract Number: 106 • 2020 Pediatric Rheumatology Symposium

    Childhood-onset Takayasu Arteritis: A Single Center Case Series of Atypical and Varied Presentations

    Uptej Khalsa1 and Imelda Balboni 1, 1Stanford University, Palo Alto, California

    Background/Purpose: Childhood-onset Takayasu arteritis is a rare inflammatory vessel disease that predominantly affects the aorta and its major branches. Clinical presentation at disease onset can…
  • Abstract Number: 2922 • 2019 ACR/ARP Annual Meeting

    Imaging Acquisition Technique Influences Interpretation of Positron Emission Tomography Vascular Activity in Large-Vessel Vasculitis

    Kaitlin Quinn1, Joel S. Rosenblum 2, Casey A. Rimland 3, K Bates Gribbons 4, Mark A. Ahlman 5 and Peter C. Grayson 6, 1Georgetown University Hospital/National Institutes of Health, Washington, DC, 2National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, 3National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD

    Background/Purpose: 18F-flurodeoxyglucose (FDG) positron emission tomography (PET) is one of several imaging modalities used in the assessment of patients with large-vessel vasculitis (LVV).  Conventionally PET…
  • Abstract Number: 257 • 2017 ACR/ARHP Annual Meeting

    The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis

    Daphne Peelen1, Ben Zwezerijnen2, Esther Nossent1, Lilian Meijboom1, Otto Hoekstra3, Conny van der Laken4 and Alexandre Voskuyl4, 1VUmc, Amsterdam, Netherlands, 2Nuclear Medicine, VUmc, Amsterdam, Netherlands, 3Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, 4Department of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands

    Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed…
  • Abstract Number: 820 • 2017 ACR/ARHP Annual Meeting

    Prognostic Value of Positron Emission Tomography in a Prospective, Longitudinal Cohort of Patients with Large Vessel Vasculitis

    Peter C. Grayson1, Sara Alehashemi2, Armin Bagheri3, Ali Cahid Civelek4, Thomas Cupps5, Mariana J. Kaplan6, Ashkan Malayeri4, Peter A. Merkel7, Elaine Novakovich8, David A. Bluemke4 and Mark Ahlman4, 1National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, 2Rheumatology, National Institutes of Health, Bethesda, MD, 3Vasculitis Translational Research Program, NIAMS, NIH, Bethesda, MD, 4Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, 5Rheumatology, Georgetown University, Bethesda, MD, 6NIAMS/NIH, Bethesda, MD, 7University of Pennsylvania, Philadelphia, MN, 8Systemic Autoimmunity Branch, NIAMS, National Institutes of Health, Bethesda, MD

    Background/Purpose: While several studies have examined the potential of 18F-flurodeoxyglucose (FDG) positron emission tomography (PET) to help establish a diagnosis of large vessel vasculitis (LVV),…
  • Abstract Number: 821 • 2017 ACR/ARHP Annual Meeting

    Discrepancies between Clinical- and Imaging-Based Assessments of Disease Activity in Takayasu’s Arteritis

    Peter C. Grayson1, Mark Ahlman2, Kathleen Marinelli3, Renee Borchin4, Simon Carette5, Nader A. Khalidi6, Carol A. Langford7, Carol A. McAlear8, Paul A. Monach9, Christian Pagnoux5, Kenneth J. Warrington10, Steven R. Ytterberg10 and Peter A. Merkel11, 1National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, 2Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, 3NIAMS, National Institutes of Health, Bethesda, MD, 4University of South Florida, Tampa, FL, 5Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 6Rheumatology, McMaster University, Hamilton, ON, Canada, 7Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 8University of Pennsylvania, Philadelphia, PA, 9Boston University School of Medicine, Boston, MA, 10Rheumatology, Mayo Clinic, Rochester, MN, 11Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: To study the relationship between clinically-determined disease activity and vascular inflammation assessed by positron emission tomography (PET) in patients with TakayasuÕs arteritis (TAK). Methods:…
  • Abstract Number: 907 • 2016 ACR/ARHP Annual Meeting

    Rituximab in Patients with Takayasu Arteritis: A Single Center Experience on Five Patients

    Giulia Pazzola1, Francesco Muratore1, Luigi Boiardi2, Mariagazia Catanoso1, Alessandra Soriano3, Pierluigi Macchioni1, Lucia Spaggiari4, Massimiliano Casali5, Nicolò Pipitone1, Niccolò Possemato6 and Carlo Salvarani1, 1Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 2Rheumatology Unit, Arcispedale S.Maria Nuova, IRCCS, Reggio Emilia, Italy, 3Rheumatology Unti, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 4Radiology, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 5Nuclear Medicine, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 6Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy

    Background/Purpose: Takayasu arteritis (TAK) is a large vessel vasculitis involving the aorta and its major branches in patients younger than 40 years. Glucocorticoids (GCs) are…
  • Abstract Number: 1319 • 2015 ACR/ARHP Annual Meeting

    18F-Fluorodeoxyglucose Positron Emission Computer Tomography and Ultrasonography for Assessing Remission in Patients with Rheumatoid Arthritis

    Charline Rinkin1, Pacôme Fosse2, Nathalie Chapelier1, Laurence Seidel3, Adelin Albert3, Roland Hustinx4 and Michel Malaise1, 1Rheumatology Department, CHU of Liège, Liège, Belgium, 2Nuclear Medicine Department, CHU of Angers, Angers, France, 3Biostatistic Department, CHU of Liège, Liège, Belgium, 4Nuclear Medicine Department, CHU of Liège, Liège, Belgium

    Background/Purpose: The disease activity score based on 28 joints (DAS-28) might not be sufficient to assess remission in rheumatoid arthritis (RA). Several studies have shown…
  • Abstract Number: 2133 • 2014 ACR/ARHP Annual Meeting

    Efficacy of Tocilizumab Therapy in Patients with Rheumatoid Arthritis Based on FDG-PET/CT

    Koichi Okamura1, Yukio Yonemoto1, Chisa Okura2 and Kenji Takagishi1, 1Orthopaedic Surgery, Gunma University, Maebashi, Japan, 2Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan

    Background/Purpose: A humanized anti-interleukin-6 receptor (anti-IL-6R) antibody, tocilizumab (TCZ), is one of the biologics and the C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR)…
  • Abstract Number: 2127 • 2014 ACR/ARHP Annual Meeting

    Subclinical Arthritis Is Detected By Macrophage Targeting and Positron Emission Tomography (PET) in Early RA Patients in Clinical Remission

    Y.Y.J. Gent1, M.M. ter Wee1, D den Uyl1, N. Ahmadi2, W.F. Lems3, O.S. Hoekstra4, A.E. Voskuyl1 and C.J. Van der Laken3, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Radiology, VU University Medical Center, Amsterdam, Netherlands, 3Rheumatology, VU Medical Center, Amsterdam, Netherlands, 4Nuclear Medicine, VU Medical Center, Amsterdam, Netherlands

    Background/Purpose: Recurrent flares in RA patients in complete remission (CR) are not an uncommon phenomenon. Studies with advanced imaging techniques have suggested that residual subclinical…
  • Abstract Number: 513 • 2014 ACR/ARHP Annual Meeting

    Analysis of Shoulder Joint Destruction in Rheumatoid Arthritis Patients Treated with Biologics

    Yukio Yonemoto, Koichi Okamura, Tetsuya Kaneko, Chisa Okura and Kenji Takagishi, Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan

    Background/Purpose The assessment of joint destruction in rheumatoid arthritis (RA) patients being treated with biologics is normally mainly carried out for small joints. There are…
  • Abstract Number: 219 • 2013 ACR/ARHP Annual Meeting

    Contrast-Enhanced Ultrasound Of The Sovraortic Arteries: The Potential Role In Monitoring Disease Activity and Response To Treatment In Large Vessel Vasculitis

    Giuseppe Germanò1, Pierluigi Macchioni1, Niccolò Possemato2 and Carlo Salvarani3, 1Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 2S.C. Reumatologia, Arcispedale Santa Maria Nuova, I.R.C.C.S., Reggio Emilia, Italy, 3Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy

    Background/Purpose: promising data has been recently published about the role of contrast-enhanced ultrasound (CEU) in the diagnosis and follow up of Takayasu arteritis (TA) -1,2-…
  • Abstract Number: 2360 • 2012 ACR/ARHP Annual Meeting

    Prevalence, Management and Outcomes of PET Positive Large Vessel Vasculitis in Difficult to Treat PMR and GCA Patients

    Pravin Patil1, Shaifali Jain2, Katerina Achilleos3, Tochukwu Adizie1, Mark Williams1, Matthew Tam2 and Bhaskar Dasgupta4, 1Rheumatology, Southend University Hospital, Westcliff on sea, United Kingdom, 2Radiology, Southend University Hospital, Westcliff on sea, United Kingdom, 3Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom, 4Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom

    Background/Purpose:  Management of PMR and GCA can be challenging in patients with persistently elevated inflammatory markers, prominent constitutional symptoms and inadequate steroid response. We undertook…
  • Abstract Number: 131 • 2012 ACR/ARHP Annual Meeting

    Subclinical Arthritis Visualised by Positron Emission Tomography and Macrophage Targeting Precedes Clinical Flare in Rheumatoid Arthritis Patients in DAS28 Remission

    Y.Y.J. Gent1, A.E. Voskuyl1, N. Ahmadi2, N. Hoetjes3 and C.J. van der Laken1, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Radiology, VU University Medical Center, Amsterdam, Netherlands, 3Nuclear Medicine & PET research, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose: Macrophages play an important role in the pathophysiology of Rheumatoid Arthritis (RA). Targeting of macrophages by (R)-[11C]PK11195 positron emission tomography (PET) has previously been successfully…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology